National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, South China Agricultural University, Guangzhou, China.
Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou, China.
Front Cell Infect Microbiol. 2020 Dec 21;10:608547. doi: 10.3389/fcimb.2020.608547. eCollection 2020.
Urinary tract infections (UTI) are common infections that can be mild to life threatening. However, increased bacterial resistance and poor patient compliance rates have limited the effectiveness of conventional antibiotic therapies. Here, we investigated the relationship between nitrofurantoin and amikacin against 12 clinical MDR uropathogenic (UPEC) strains both and in an experimental model. synergistic effects were observed in all 12 test strains by standard checkerboard and time-kill assays. Importantly, amikacin or nitrofurantoin at half of the clinical doses were not effective in the treatment of UPEC infections in the model but the combination therapy significantly increased survival from infections caused by all 12 study UPEC strains. Taken together, these results demonstrated synergy effects between nitrofurantoin and amikacin against MDR UPEC.
尿路感染(UTI)是一种常见的感染,可轻可重,甚至可能危及生命。然而,细菌耐药性的增加和患者的低依从性限制了传统抗生素治疗的效果。在这里,我们研究了呋喃妥因和阿米卡星对 12 株临床多重耐药尿路致病性大肠杆菌(UPEC)株的关系,包括在实验模型中。通过标准棋盘和时间杀伤试验,在所有 12 株测试菌株中均观察到协同作用。重要的是,在 模型中,阿米卡星或呋喃妥因的临床剂量减半对 UPEC 感染的治疗无效,但联合治疗显著提高了所有 12 株研究 UPEC 菌株引起的感染的存活率。总之,这些结果表明呋喃妥因和阿米卡星对多重耐药 UPEC 具有协同作用。